Piroxicam attenuates 3-nitropropionic acid-induced brain oxidative stress and behavioral alteration in mice

References

• Ahuja M, Bishnoi M, Copra K. (2008). Protective effect of minocycline, a semi synthetic second generation tetracycline against 3-nitropropionic acid induced neurotoxicity. Toxicology 244:111–22
   PubMed Web of Science ®Google Scholar
• Beal MF, Brouillet E, Jenkins BG, et al. (1993). Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181–92
   PubMed Web of Science ®Google Scholar
• Bishnoi M, Patil CS, Kumar A, Kulkarni SK. (2005). Protective effects of nimesulide (COX Inhibitor), AKBA (5-LOX Inhibitor), and their combination in aging-associated abnormalities in mice. Methods Find Exp Clin Pharmacol 27:465–70
   PubMedGoogle Scholar
• Bishnoi M, Patil CS, Kumar A, Kulkarni SK. (2007). Co-administration of acetyl-11-keto-beta-boswellic acid, a specific 5-lipoxygenase inhibitor, potentiates the protective effect of COX-2 inhibitors in kainic acid-induced neurotoxicity in mice. Pharmacol 79:34–41
   PubMed Web of Science ®Google Scholar
• Brouillet E, Conde F, Beal MF, Hantraye P. (1999). Replicating Huntington’s disease phenotype in experimental animals. Prog Neurobiol 59:427–68
   PubMed Web of Science ®Google Scholar
• Claiborne A. (1985). Handbook of methods for oxygen radical research. London: CRC Press
   Google Scholar
• Cowan CM, Raymond LA. (2006). Selective neuronal degeneration in Huntington’s disease. Curr Top Dev Biol 75:25–71
   PubMed Web of Science ®Google Scholar
• Ellman GL. (1959). Tissue sulfhydryl groups. Arch Biochem Biophys 82:70–7
   PubMed Web of Science ®Google Scholar
• Fontaine M, Geddes J, Banks A, Butterfield DA. (2000). 3-Nitropropionic acid-induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington’s disease. Brain Res 858:356–62
   PubMed Web of Science ®Google Scholar
• Gelvan D, Saltman P. (1990). Different cellular targets of Cu- and Fe-catalyzed oxidation observed using a Cu-compatible thiobarbiturate acid assay. Biochim Biophys Acta 1035:353–60
   PubMed Web of Science ®Google Scholar
• Hunter AJ, Hatcher J, Virley D, et al. (2000). Functional assessments in mice and rats after focal stroke. Neuropharmacol 39:806–16
   PubMed Web of Science ®Google Scholar
• James WS, Wang J, Wang X, et al. (2005). Mitochondria play a central role in estrogen-induced neuroprotection. Curr Drug Targets-CNS Neurol Dise 4:69–83
   PubMedGoogle Scholar
• Kalonia H, Kumar P, Kumar A, Nehru B. (2009). Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. Neurosci Bull 25:343–52
   PubMedGoogle Scholar
• Katzung BG. (2001). Basic and clinical pharmacology. 10th ed. New York: McGraw-Hill
   Google Scholar
• Kulkarni SK. (1999). Hand book of experimental pharmacology. New Delhi: Vallabh Prakashan
   Google Scholar
• Kumar P, Kalonia H, Kumar A. (2009). Lycopene modulates nitric oxide pathways against 3-nitropropionic acid-induced neurotoxicity. Life Sci 85:711–18
   PubMed Web of Science ®Google Scholar
• Kumar P, Kumar A. (2008). Prolonged pretreatment with carvedilol prevents 3-NP acid-induced behavioral alterations and oxidative stress in rats. Pharmacol Rep 60:706–15
   PubMedGoogle Scholar
• Kumar P, Padi SS, Naidu PS, Kumar A. (2007). Cyclooxygenase inhibition attenuates 3-nitropropionic acid-induced neurotoxicity in rats: possible antioxidant mechanisms. Fund Clin Pharmacol 21:297–306
   PubMed Web of Science ®Google Scholar
• Leegwater-Kim J, Cha JJ. (2004). The paradigm of Huntington’s disease: therapeutic opportunities in neurodegeneration. NeuroRx 1:128–38
   PubMedGoogle Scholar
• Liot G, Bossy B, Lubitz S, et al. (2009). Complex-II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA- and ROS-dependent pathway. Cell Death Differ 16:899–909
   PubMed Web of Science ®Google Scholar
• Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. (1951). Protein measurement with the Folin phenol reagent. J Biol Chem 193:265–75
   PubMed Web of Science ®Google Scholar
• Ludolph AC, He F, Spencer PS, et al. (1991). 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Canad J Neurol Sci 18:492–8
   PubMed Web of Science ®Google Scholar
• Mrak RE, Griffin WS. (2005). Potential inflammatory biomarkers in Alzheimer’s disease. J Alzheimers Dis 8:369–75
   PubMed Web of Science ®Google Scholar
• Reynolds DS, Carter RJ, Morton J. (1998). Dopamine modulates the susceptibility of striatal neurons to 3-nitropropionic acid in the rat model of Huntington’s disease. J Neurosci 18:10116–27
   PubMedGoogle Scholar
• Reynolds IJ, Hastings TG. (1995). Glutamate induces the production of reactive oxygen species in cultured forebrain neurons following NMDA receptor activation. J Neurosci 15:3318–27
   PubMed Web of Science ®Google Scholar
• Schulz JB, Matthews RT, Henshaw DR, Beal MF. (1996). Neuroprotective strategies for treatment of lesions produced by mitochondrial toxins: implications for neurodegenerative diseases. Neuroscience 71:1043–104
   PubMed Web of Science ®Google Scholar
• Shivasharan BD, Nagakannan P, Thippeswamy BS, et al. (2013). Protective effect of Calendula officinalis Linn. flowers against 3-nitropropionic acid induced experimental Huntington’s disease in rats. Drug Chem Toxicol 36:466–73
   PubMed Web of Science ®Google Scholar
• Soliman Y, Jackson T, Mazzio E, Soliman KFA. (2009). The effects of piroxicam in the attenuation of MPP+/MPTP toxicity in vitro and in vivo. Neurochem Res 34:304–10
   PubMedGoogle Scholar
• Song YN, Li HZ, Zhu JN, et al. (2006). Histamine improves rat rota-rod and balance beam performances through H2 receptors in the cerebellar interpositus nucleus. Neurosci 140:33–43
   PubMed Web of Science ®Google Scholar
• Tobinick EL, Gross H. (2008). Rapid cognitive improvement in Alzheimer’s disease following perispinal etanercept administration. J Neuroinflam 5:2
   PubMed Web of Science ®Google Scholar
• Tunez I, Inmaculada T, Perez-De La Cruz V, Santamaria A. (2008). 3-Nitropropionic acid as a tool to study the mechanisms involved in Huntington’s disease: past, present and future. Molecules 15:878–916
   Google Scholar
• Walling HW, Baldassare JJ, Westfall TC. (1998). Molecular aspects of Huntington’s disease. J. Neurosci Res 54:301–8
   PubMedGoogle Scholar
• Yan X, Wang S, Hou H, et al. (2007). Lithium improves the behavioral disorder in rats subjected to transient global cerebral ischemia. Behav Brain Res 177:282–9
   PubMed Web of Science ®Google Scholar